Several phase II–III studies have shown that the EGFR-targeting monoclonal antibody, cetuximab, offers clinical benefit for patients with SCCHN. Cetuximab monotherapy is active in patients whose ...
The authors conclude that KRAS mutation status can be used to identify the subgroup of patients with irinotecan-refractory metastatic CRC who are most likely to respond to cetuximab.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback